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Summary: To analyze the pathophysiological changes ot the airways in emphysema,
bronchial responsiveness and the generation of leukotrienes 84 (LT84) and C4 (LTC4)
by peripheral leucocytes were examined in 22 patients with emphysema. The subjects
were divided into two groups according to the presence or absence of IgE antibodies
against inhalant allergens; RAST positive group and RAST negative group. 1. Smoking
history, mean CT number and mean maximum % low attenuation area (%LAA) <-950HU
of the lung on high resolution computed tomography (HRCT), and OLco value suggested
that there were emphysematous changes of the lung in all subjects. However, these
findings were not different between the two groups. 2. The level of serum IgE was
significantly higher in RAST positive group than in RAST negative group. 3. The mean
%increase in FEV1. 0 after inhalation of j3-agonists was higher in RAST positive group
than in RAST negative group. The %increase more than 15% was found in 4 of the 9
subjects (44.4%) in RAST positive group and 2 of the 12 (16.7%) in RAST negative group.
4. The generation of LTC4 by leucocytes was significantly higher in RAST positive group
than in RAST negative group (p<O.01). The generation of LT84 was not significantly
different between the two groups.
The results suggest that IgE-mediated allergy participates in the bronchial responsive-
ness of patients with emphysema.
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Introduction
IgE-mediated allergy induces pathophysiological
changes of the airways in asthma'-3). An asthma attack
can be divided into two phases according to tne time it
occurs after bronchial challenge with an allergen:
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immediate asthmatic reaction (IAR) at about 30 min,
and late asthmatic reaction (LAR) at 6-8 hours after
the challenge. In the IAR, chemical mediators such as
histamine and leukotrienes are released from tissue
mast cells5,6), while in the LAR, inflammatory cell
infiltration is observed, accompanied by the release of
various humoral factors including chemical mediators
7·10)
In asthma attacks, wheezing and dyspnea are char-
acteristically observed due to bronchoconstriction,
mucus hypersecretion, edema of mucous membra-
ne,and bronchiolar obstruction11,12), In contrast,
wheezing and exertional dyspnea are often observed in
patients with pulmonary emphysema. Pulmonary em-
physema is a disease accompanied with destruction of
the lung. However, the pathophysiological changes in
the airways of pulmonary emphysema is not well
known.
In this study, to evaluate the airway response in
pulmonary emphysema, the generation of leukotrienes
B4 (LTB4) and C4 (LTC4) by leucocytes was exam-
ined in patients with the disease assessed by high
resolution computed tomography (HRCT) and divided
into the two groups according to IgE-mediated allergy,
Subjects and Methods
The subjects of this study was 22 patients (all
males) with pulmonary emphysema. The mean age
was 69.9 years (56-81years) and the mean age at onset
of the disease was 62.8years (52-74years). The sub-
jects were divided into two groups according to the
presence or absence of IgE antibodies against inhalant
allergens; house dust mite (HDm), cockroach, and
Candida albicans. IgE antibodies were found in 9
patients (6 for HDm, 2 for Candida, and 1 for
cockroach)(RAST possitive group), and not in residual
13 patients (RAST negative group).
CT scans were performed on a Toshiba Xpeed
scanner (2.7s, 200mAs, 120Kvp) without infusion of
contrast medium, using 2mm collimation (high resolu-
tion computed tomography: HRCT) in patients breath-
holding at full inspiration. The lungs were scanned as
preselected three anatomic levels; (1) top of the aortic
arch, (2) origin of the lower lobe bronchus, (3) three
cm above the top of the diaphragm, as reported by
Miniati, et al. l3). Inspiratory HRCT scans were eva-
luated quantitatively by measuring the percentage of
lung area with CT number <-950 Hounsfield Unit
(HU) (%low attenuation area; %LAA). The average of
the CT numbers in three anatomic levels was ex-
pressed as the mean CT number. The maximum
%LAA among the three anatomic levels of the lung
was expressed as representative %LAA in each patient
with pulmonary emohysema.
The generation of leukotrienes, LTB4 and LTC4 ,by
peripheral leucocytes was assessed by a HPLC meth-
od. Affer buffy coat was separated by adding a quater
volume of 6% dextran, the number of the cells was
adjusted to 5 X 106 cells Iml in Tris ACM, and then
Ca ionophore A23187 (l,ug) was added to the cell
suspension. The mixed solution was incubated for 15
min at 37 "C, after then, supernatant was taken into the
syringe filter (Toyo Roshi Co, Japan). The HPLC
analysis for LTB4 and LTC4 was performed by a
method described by Lam et al. 14). The results were
expressed as ng/5 X 106cells.
Bronchial reactivity to methacholine was measured
by an Astograph (TCK 6100, Chest Co, Japan).
Different concentrations of methacholine (49, 98, 195,
390,781, 1563,3125,6250, 12500, and 25000,ug/rnl)
were prepared for bronchial challenge according to the
method used by Chai et al. IS). The increase of total
respiratory resistance (Rrs) after methacholine inhala-
tion was measured by the oscillation methodI6). A
methacholine concentration causing a significant in-
crease in Rrs was assessed as Cmin (minimum
concentration)17). All medications were stopped 12
hours prior to the examination.
Pulmonary function test, forced vital capacity
(FVC), forced expiratory volume in one second
(FEV1.0), and diffusing capacity for carbone mono-
xide (DLco) was measured in all patients using a
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Chestac 33 (Chest Co, Japan).
IgE antibodies against inhalant allergens, house dust
mite, cockroach, and Candida, were estimated by
radioallergosorbent test (RAST), and serum IgE levels
were evaluated by radioimmunosorbent test (RIST).
Statistically significant differences of the mean were
estimated using the Student's t test. A value of <0.05
was regarded as significant.
Results
Table 1 represents the characteristics of RAST
positive and RAST negative group. Age and age at
onset of the disease were not different between the
two groups. Serum IgE level was significantly higher
in RAST positive group than in RAST negative group.
Smoking history was more than 40 pack-year and the
mean CT number was less than -950HU in both
groups Table2l•
The mean of maximum %LAA was rather higher in
RAST positive group (60.4 ± 12.6%) (mean ±
SD) compared to the mean in RAST negative group
(55.8 ± 9.1%)(Fig.l). However, this was not si-
gnificant. The DLco value was not different in the two
groups; 65.7 ± ILl % (%predicted) in RAST posi-
tive group and 65.9 ± 21.7% in RAST negative
group (Fig.2).
The mean %increase in FEV1.0 after inhalation of
j3 -receptor stimulating agents was higher in RAST
positive group (13.2 ± 5.9%) than in RAST negative
group (8.6 ± 7.0%). A large number of patients in
the two groups showed the % increase in FEV1.0
value less than 15%. However, the %increase more
than 15% was more frequently found in RAST
positive group (4/9;44.4%) than in RAST negative
group (2/12;16.7%)(Fig.3).
Bronchial hyperresponsiveness was not observed in
all subjects except each one case in the two groups.
*RAST score against inhalant allergens, a;p<O.Ol.
*HRCT; high resolution computed tomography
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Fig.l. %LAA of the lung in patients with pulmonary
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inhalant allergens. LAA; low attenuation area
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Table 2. Characteristics of patients with pulmonary
emphysema studied in relation to smoking
history and mean CT number on HRCT*
Table 1. Characteristics of patients with pulmonary
emphysema studied in relation to RAST score
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Fig.4. LTB4 ( • ) and LTC4 ( 0 )generation by
Ieucocytes in patients with pulmonary emp-
hysema in relation to IgE antibodies against
inhalant allergens. a; p<O.Ol.
Discussion
Emphysema is defined as a condition of the lung
characterized by abnormal, permanent enlargement of
the airspaces distal to the terminal bronchiole, accom-
panied by destruction of their walls l8l• Pulmonary
emphysema is diagnosed by sujective and objective
symptoms, and clinical findings including chest X ray
and pulmonary function such as forced expiratory
The generation of LTB4 by leucocytes was 104.3
± 36.5ng/5 X 106 cells in RAST positive group and
80.2 ± 43.9ng/5 X 106 cells in RAST negative group.
There was no significant difference between the two
groups. The production of LTC4 was significantly
higher in RAST positive group (43.4 ± 30.lng/5 X
106 cells) compared to the production in RAST
negative group (10.9 ± 14.6ng/5 X 106cells) (p,O.OI)
(Fig.4).
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Fig.3. %Increase in FEVl.O after {3 -agonists inhala-
tion in patients with pulmonary emphysema in
relation to IgE antibodies
Fig.2. DLco value (%predicted) in patients with
pulmonary emphysema in relation to IgE anti-
bodies against Inhalant allergens.
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volume in one second (FEV1.0), residual volume
(RV), and DLco. In recent years, it has become clear
that computed tomography (CT) is the most accurate
imaging method for diagnosing emphysema in vivo. It
has been shown that the relative areas of the lungs that
has attenuation values lower than -950HU on high
resolution CT scans obtained at full inspiration is an
objective measure of the extent of pulmonary em-
physema19.201.
Emphysematous changes on chest X ray films,
FEV1.0<80%, and DLco<80% were observed in all
subjects studied. Furthermore, the results of mean CT
number and maximum %LAA suggest that all subjects
had emphysematous changes of the lung. The extent of
emphysematous changes of the lung can be analyzed
by pulmonary function and mean CT number and
%LAA of the lung. However, airway responsiveness
of pulmonary emphysema is not well known despite
wheezing offen accompanied with exertional dyspnea.
In this study, airway responsiveness was analyzed in
patients with emphysema in relation to IgE-mediated
allergy. The mean of %increase in FEV1.0 after
inhalation of p-agonists was low in RAST positive
group (8.6%)and RAST negative group (13.2%).
However, the %increase in FEVl.O exceeding 15%
was more frequently observed in RAST positive group
(44.4%) compared to the %increase in RAST negative
group (16.7%). The results suggest that airway re-
sponsivness to p-agonists is higer in RAST positive
group than in RAST negative group.
Cysteinyl leukotrienes, LTC4, LTD4, and LTE4,
have bronchoconstrictory action21J, increase mucus
formation221, and bronchial wall edema231. It has been
shown that the generation of LTC4 by leucocytes was
significantly higher in asthmatic children than in
healthy controls24). The report also demonstrated that
leucocytes from patients with a history of severe
asthma displayed a higher LTC4 formation than
leucocytes from patients with less severe disease. Our
results on pulmonary emphysema revealed that the
generation of LTC4 by leucocytes was significantly
higher in patients of RAST positive group than in
those of RAST negative group.
The data from %increase in FEVl.O after f3-a-
gonists inhalation and LTC4 generation by leucocytes
might suggest that airways dysfunction in pulmonary
emphysema is more frequently and more strongly
observed in patients with IgE-mediated allergy than in
those without the allergy.
Leukotriene B4 (LTB4) stimulates neutrophil che-
motaxis and activation of the cells, leading to the
release of mediators, enzymes, and superoxide25). It
has been reported that neutrophil inflammation
enhances bronchial hyperresponsiveness26.271. Our re-
sults in this study on pulmonary emphysema demon-
strated that the generation of LTB4 by leucocytes was
higher in patients with IgE-mediated allergy than in
those without the allergy. However, this was not
significant.
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肺気腫患者の気道病変を解析する目的で,22
例の肺気腫患者を対象に,その気道反応および白
血球のロイコトリエンB4,C4産生能について検
討を加えた｡この際対象症例はIgE抗体の有無に
よってRAST陽性症例RAST陰性症例に分類さ
RespirDis141:540-545,1990.
れた｡1.喫煙歴,平均CT値,highresolutionco-
mputedtomography(HRCT)上の-950HU以下の
鞄lowatenuationarea(%LAA),DLcoなどの値は,
いずれも対象症例が高度な気腫化病変を有してい
ることを示した｡2.血清IgE値は,RAST陽性
例で陰性例に比べ有意の高値を示した｡3.β受
容体刺激薬吸入後のFEV1.0の増加は,RAST陽
性例で陰性例に比べ高度であった｡そして,吸入
後のFEV1.0が 15%以上の増加を示した症例は,
RAST陽性例では9例中4例(44.4%),陰性例で
は12例中2例(16,7%)であった｡4.白血球の
LTC4産生量は,RAST陽性例で陰性例に比べ有
意に高い値であったが,LTB4産生は両者間に有
意の差は見られなかった｡以上の結果より,IgE
にmediateされるアレルギー反応が,肺気腫患者
の気道反応に関与している可能性が示唆された｡
